ARTICLE | Discovery & Translation
BioCentury’s roundup of translational innovation: Embark/Novo discover new obesity target, Canbridge delivers large DMD gene, and more
By Danielle Golovin, Senior Biopharma Analyst
November 20, 2024 11:33 PM UTC
Embark Laboratories ApS and collaborators from two Novo Nordisk Foundation Centers showed in Nature that activation of the GPCR NK2R can suppress appetite without nausea, and increase energy expenditure without affecting lean mass, addressing two limitations of current obesity drugs. A third benefit was its ability to increase insulin sensitivity.
Analysis of data from the HugeAMP Type 2 Diabetes Knowledge Portal, which contains human genetic associations assembled from over 350 studies, identified an association between NK2R expression and hemoglobin A1c levels, a clinical indicator of glucose control and diabetes progression. …
- SEO Powered Content & PR Distribution. Get Amplified Today.
- PlatoData.Network Vertical Generative Ai. Empower Yourself. Access Here.
- PlatoAiStream. Web3 Intelligence. Knowledge Amplified. Access Here.
- PlatoESG. Carbon, CleanTech, Energy, Environment, Solar, Waste Management. Access Here.
- PlatoHealth. Biotech and Clinical Trials Intelligence. Access Here.
- Source: https://www.biocentury.com/article/654263/science-spotlight-a-new-obesity-target-may-avoid-nausea-muscle-loss